Does semaglutide actually help with weight loss?

The myth that these medicines 'do the work for you'

One of the most common things people believe when they first hear about semaglutide is that the injection handles everything on its own, that you carry on eating the same way and the weight simply disappears. It is a forgivable assumption, and it is worth setting it down gently rather than dismissing it. If you want a clear answer to whether semaglutide genuinely helps people lose weight, the evidence and what it actually means in practice is worth reading first. What semaglutide actually does is change the biological signals that drive hunger. It does not burn fat directly or override your metabolism. What it does is make the relentless pull of appetite considerably quieter, which makes the reduced-calorie diet and increased activity that clinicians ask you to pair with treatment far more achievable than many people experience without it.

Both Wegovy's clinical licence and NICE's appraisal of semaglutide (TA875) specify that treatment should be used alongside a reduced-calorie diet and increased physical activity. The medicine creates the biological conditions for change; sustained effort shapes the outcome. Understanding that distinction tends to set more realistic, and ultimately more satisfying, expectations.

If you are exploring what semaglutide-based weight loss actually looks like in practice, that fuller picture is worth reading before you start treatment.

How semaglutide signals your body to eat less

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 is a hormone your gut releases naturally after eating, it tells your pancreas to release insulin, slows gastric emptying, and sends fullness signals to the appetite centres in your brain. Semaglutide mimics this hormone but with a much longer duration of action than the natural version, which is why a single weekly injection can suppress appetite across seven days.

The practical effect for most people is a reduced desire to eat large portions, less preoccupation with food between meals, and a lower tendency to eat past fullness. Some people also notice that certain foods (particularly very sweet or fatty ones) become less appealing. These are not side effects in the conventional sense; they reflect the medicine working as intended.

How semaglutide produces these appetite changes is covered in more depth at how Wegovy helps you lose weight, including what happens at the level of the brain's reward signalling.

What the trial results show, and how to read them honestly

The STEP 1 trial followed around 1,900 adults with obesity over 68 weeks. Participants receiving semaglutide 2.4mg alongside lifestyle guidance lost an average of roughly 15% of their starting body weight, compared with around 2.4% in the placebo group. Those are averages: some participants lost considerably more, some less. A question our prescribers hear regularly is whether someone can expect to land at the average. The honest answer is that nobody can predict an individual's response with certainty before treatment begins.

Since then the MHRA has approved a 7.2mg single-dose weekly pen, with trials reporting an average weight loss of around 20.7% over 72 weeks at that dose, narrowing the gap with tirzepatide results. For context on how semaglutide compares with tirzepatide across the evidence, the Wegovy pricing and treatment page outlines the options and what is included in a private prescription route.

The NHS medicines page for semaglutide gives a clear patient-level summary of expected effects, common side effects, and how to use the injection, a useful reference once treatment is under way.

Who semaglutide is licensed for, and what a prescriber actually checks

In the UK, Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related condition is present, for example, high blood pressure, raised cholesterol, obstructive sleep apnoea, or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, with a typical adjustment of 2.5 kg/m² downward. A prescriber reviews the complete picture, not just a BMI figure.

There are circumstances where semaglutide is not recommended: during pregnancy, when breastfeeding, or when trying to conceive. It is not licensed for under-18s. Anyone with a personal or family history of medullary thyroid carcinoma, or certain conditions affecting the pancreas, would need that discussed with a prescriber before any treatment.

The consultation also covers current medicines. Women taking oral contraceptives alongside tirzepatide are advised to use an additional non-oral method for the first four weeks of treatment and after each dose increase; for semaglutide there is no equivalent evidence of reduced pill effectiveness, though it is always worth raising with your prescriber.

If you want to think through the individual picture before a formal consultation, what to know before using semaglutide for weight loss covers the key preparation questions. When you are ready, speaking to our prescribers is the natural next step, our clinical team, led by a GPhC-registered Independent Prescriber, reviews every consultation personally, the same day it is submitted.